503657428 01/20/2016

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT3704062

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
MITSUBISHI TANABE PHARMA CORPORATION	05/17/2011

RECEIVING PARTY DATA

Name:	ENVIVO PHARMACEUTICALS, INC.	
Street Address:	500 ARSENAL STREET	
City:	WATERTOWN	
State/Country:	MASSACHUSETTS	
Postal Code:	02472	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	15002163

CORRESPONDENCE DATA

Fax Number: (202)626-1700

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 212-326-3939

Email: kmhutchison@jonesday.com

Correspondent Name: JONES DAY

Address Line 1: 222 EAST 41ST ST

Address Line 4: NEW YORK, NEW YORK 10017

ATTORNEY DOCKET NUMBER:	013171-0044-999
NAME OF SUBMITTER:	PAUL L. SHARER
SIGNATURE:	/Paul L Sharer/
DATE SIGNED:	01/20/2016

Total Attachments: 1

source=Mitsubishi_EnVivoAssignment#page1.tif

PATENT 503657428 REEL: 037538 FRAME: 0290

Please return signed/recorded to: Jones Day Intellectual Property Group 51 Louistana Avenue, N.W. Washington, D.C. 20001-2113 Attorney Reference: 013171-0004-999 Client Reference: EVP-52WO

ASSIGNMENT OF PATENT RIGHTS

WHEREAS, Mitsubishi Tanabe Pharma Corporation of 2-6-18, Kitahama, Chuo-ku, Osaka-shi, Osaka 541-8505 Japan (hereinafter "ASSIGNOR"), the co-owner of the applications for Letters Patents and/or the issued Letters Patents as listed herein,

AND EnVivo Pharmaceuticals, Inc.

500 Arsenal Street Watertown, Massachusetts 02472 United States of America

(hereinafter "ASSIGNEE"), have entered into a Joint Development Agreement and Assignment of Intellectual property rights encompassing <u>International Application No. PCT/US2011/036844</u> filed on <u>May 17, 2011</u> and all applications from which it claims priority, and all applications claiming priority thereto; and

NOW, THEREFORE, in consideration of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the said ASSIGNOR, does hereby confirm and memorialize any prior sale, assignment and transfer to ASSIGNEE, its successors, assigns and legal representatives, the full and exclusive right, title and interest to the said patent in to the said invention in the United States of America and all countries worldwide as described in the aforesaid applications, and to the said applications and all applications claiming priority thereto, and to all continuations, divisions, and renewals thereof. and all Patents of the United States and any and all countries worldwide which may be granted thereon, and all reissues and extensions thereof; and all applications for industrial property protection, including, without limitation, all applications for patents, utility models, and designs which may hereafter be filed for said invention in any country or countries foreign to the United States, together with the right to file such applications for all forms of industrial property protection and the right to claim for the same the priority rights derived from said United States or International applications under the Patent Laws of the United States, the International Convention for the Protection of Industrial Property, or any other international agreement or the domestic laws of the country in which any such application(s) is/are filed, as may be applicable, together with all of the goodwill associated with such intellectual property and all rights to sue and recover for any past, present or future infringement, dilution, damage or injury (and including the right to take over and continue any and all existing suits) to any of the foregoing and collect profits or damages with respect to same, the same to be held and enjoyed hereinafter by ASSIGNEE for its own use and for the use of its successors and assigns.

IN WITNESS WHEREOF, we hereunto set our respective signatures below and cause this Assignment to be executed on the date set forth above.

BY: Mitsubishi Tanabe Pharma Corporation

Name: Michihiro Tsuchiya

Title: President & Representative Director, CEO

EnVivo Pharmaceuticals, inc.

Name: Kees BEEN Robert Weinskoff

Title: President and Chief Executive Officer

PATENT REEL: 037538 FRAME: 0291

RECORDED: 01/20/2016